

Iduronate 2 Sulfatase Treatment Pipeline Review H2 2016

Iduronate 2 Sulfatase Therapeutic Pipeline Market Review, H2 2016

PUNE, INDIA, September 13, 2016

/EINPresswire.com/ -- The report provides comprehensive information on the [Iduronate 2 Sulfatase](#) (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics development and features dormant and discontinued projects.

Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Complete Report@ <https://www.wiseguyreports.com/reports/636737-iduronate-2-sulfatase-alpha-review-h2-2016>



Scope

- The report provides a snapshot of the global therapeutic landscape for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)
- The report reviews Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics and enlists all their major and minor projects
- The report assesses Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/636737-iduronate-2-sulfatase-alpha-review-h2-2016>

Table of Content

Products Glance 11

Late Stage Products 11

Early Stage Products 12

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) -

Products under Development by Companies 13

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) -

Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) -

Companies Involved in Therapeutics Development 22

AngioChem Inc. 22

ArmaGen Inc. 23

Bioasis Technologies Inc. 24

Green Cross Corporation 25

JCR Pharmaceuticals Co., Ltd. 26

Laboratorios Del Dr. Esteve S.A. 27

RegenxBio Inc. 28

Sangamo BioSciences, Inc. 29

Shire Plc 30

Have any query@ <https://www.wiseguyreports.com/enquiry/636737-iduronate-2-sulfatase-alpha-review-h2-2016>

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) -

Drug Profiles 31

AGT-182 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

EGT-301 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

idursulfase - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

idursulfase beta - Drug Profile 36

Product Description 36
Mechanism Of Action 36
R&D Progress 36
JR-032 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
JR-141 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
MTf-I2S - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
MTfp-I2S - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Recombinant Iduronate 2-Sulfatase Replacement for Mucopolysaccharidosis II - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
RGX-121 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
SB-913 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=636737

Continued...

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/344514335>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.